DIABETES
VOL. 45, SUPPLEMENT 3, JULY 1996
Transgenic Mouse and Gene Therapy
Kenji Harada, Hitoshi Shimano, Shun Ishibashi, and Nobuhiro Yamada
In the transgenic mouse, a specific gene can be transduced or
deleted to study its function and relation to human diseases.
Recently, various lines of transgenic mice that overexpress or
lack a specific gene have been established and are available to
study the pathophysiology of human diseases, including
atherosclerosis, diabetes, and hyperlipidemia. We have
established transgenic mouse lines with an integrated rat
apolipoprotein (apo) E gene under control of the metallothionein
promoter. Overexpression of apoE in the liver reduced plasma
cholesterol and triglyceride levels and prevented diet-induced
hypercholesterolemia. Another transgenic model with
overexpression of apoE under control of the H2 Ld promoter in the
arterial wall was established. In this model, the formation of
fatty streak lesions was markedly inhibited, suggesting that apoE
has antiatherogenic actions. Finally, we discuss gene therapy,
which will be an important therapeutic approach to correct
genetic abnormalities found in metabolic diseases. Diabetes
45 (Suppl. 3):S129-S132. l996
Copyright © 1996 American Diabetes Association
Last updated: 7/15/96
For ADA Related Issues contact CustomerService@diabetes.org
For Technical Issues contact webmaster@diabetes.org